Mostrar el registro sencillo del ítem

dc.contributor.authorKrstić, Luna
dc.contributor.authorGonzález García, María Jesús 
dc.contributor.authorDiebold Luque, María Yolanda 
dc.date.accessioned2022-09-26T08:33:06Z
dc.date.available2022-09-26T08:33:06Z
dc.date.issued2021
dc.identifier.citationMolecules, 2021,Vol. 26, Nº.2, 370, 26 pp.es
dc.identifier.issn1420-3049es
dc.identifier.urihttps://uvadoc.uva.es/handle/10324/55631
dc.descriptionProducción Científicaes
dc.description.abstractNature has become one of the main sources of exploration for researchers that search for new potential molecules to be used in therapy. Polyphenols are emerging as a class of compounds that have attracted the attention of pharmaceutical and biomedical scientists. Thanks to their structural peculiarities, polyphenolic compounds are characterized as good scavengers of free radical species. This, among other medicinal effects, permits them to interfere with different molecular pathways that are involved in the inflammatory process. Unfortunately, many compounds of this class possess low solubility in aqueous solvents and low stability. Ocular pathologies are spread worldwide. It is estimated that every individual at least once in their lifetime experiences some kind of eye disorder. Oxidative stress or inflammatory processes are the basic etiological mechanisms of many ocular pathologies. A variety of polyphenolic compounds have been proved to be efficient in suppressing some of the indicators of these pathologies in in vitro and in vivo models. Further application of polyphenolic compounds in ocular therapy lacks an adequate formulation approach. Therefore, more emphasis should be put in advanced delivery strategies that will overcome the limits of the delivery site as well as the ones related to the polyphenols in use. This review analyzes different drug delivery strategies that are employed for the formulation of polyphenolic compounds when used to treat ocular pathologies related to oxidative stress and inflammation.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherMDPIes
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectPolyphenolses
dc.subjectFarmacología oculares
dc.subjectOxidative stresses
dc.subjectAntioxidanteses
dc.subjectInflammationes
dc.titleOcular delivery of polyphenols: meeting the unmet needses
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.holder© 2021 The Authorses
dc.identifier.doi10.3390/molecules26020370es
dc.relation.publisherversionhttps://www.mdpi.com/1420-3049/26/2/370es
dc.identifier.publicationfirstpage1es
dc.identifier.publicationissue2es
dc.identifier.publicationlastpage26es
dc.identifier.publicationtitleMoleculeses
dc.identifier.publicationvolume26es
dc.peerreviewedSIes
dc.description.projectMinisterio de Ciencia, Innovación y Universidades - Fondo Europeo de Desarrollo Regional (RTI2018-094071-B-C21)es
dc.description.projectEuropean Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Initial Training Network (ITN) “IT-DED3” (H2020-MSCA-ITN-2017) grant agreement No. 765608es
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/765608
dc.identifier.essn1420-3049es
dc.rightsAtribución 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones
dc.subject.unesco3201.09 Oftalmologíaes


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem